| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/J.1552-4604.1996.TB04207.X |
| P8608 | Fatcat ID | release_f3kjewpfdrbstb572v5rpsjawu |
| P698 | PubMed publication ID | 8728345 |
| P2093 | author name string | A Nicholls | |
| M Hale | |||
| R Bullingham | |||
| S Monroe | |||
| P2860 | cites work | A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability | Q30062775 |
| Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion | Q41698111 | ||
| Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. | Q52312810 | ||
| P433 | issue | 4 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| bioavailability | Q461809 | ||
| P304 | page(s) | 315-324 | |
| P577 | publication date | 1996-04-01 | |
| P1433 | published in | The Journal of Clinical Pharmacology | Q7743562 |
| P1476 | title | Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration | |
| P478 | volume | 36 |
| Q59051193 | A Review of the Potential Utility of Mycophenolate Mofetil as a Cancer Therapeutic |
| Q37050337 | A perspective on efflux transport proteins in the liver |
| Q38737248 | Amorphous Solid Dispersions or Prodrugs: Complementary Strategies to Increase Drug Absorption |
| Q77166109 | Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid |
| Q38817096 | Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients |
| Q34573738 | Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients |
| Q46787320 | Clinical pharmacokinetics of mycophenolate mofetil |
| Q41440255 | Clinically significant drug interactions with new immunosuppressive agents |
| Q73779388 | Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability |
| Q44712852 | Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors |
| Q43359715 | Comparative gastrointestinal effects of mycophenolate mofetil capsules and enteric-coated tablets of sodium-mycophenolic acid in beagle dogs |
| Q35486258 | Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation |
| Q38768108 | Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis. |
| Q34702634 | Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite |
| Q46512740 | Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function |
| Q40369419 | Effect of long-term coadministration of compound glycyrrhizin tablets on the pharmacokinetics of mycophenolic acid in rats. |
| Q36025085 | Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients |
| Q45289872 | Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil |
| Q44663050 | Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients |
| Q28354181 | Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes |
| Q44328108 | High-performance liquid chromatographic method for mycophenolic acid and its glucuronide in serum and urine |
| Q74756161 | High-performance liquid chromatography determination of mycophenolic acid and its glucuronide metabolite in human plasma |
| Q50703377 | Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. |
| Q38340831 | Immunosuppressive drug therapy--biopharmaceutical challenges and remedies |
| Q32060938 | Immunosuppressive drugs in paediatric liver transplantation |
| Q46006810 | Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients. |
| Q46554388 | Impact of mycophenolate mofetil loading on drug exposure in the early posttransplant period |
| Q45188818 | Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients |
| Q53911174 | Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. |
| Q100954649 | Investigating a Modified Apparatus to Discriminate the Dissolution Capacity in Vitro and Establish an IVIVC of Mycophenolate Mofetil Tablets in the Fed State |
| Q35827831 | Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients |
| Q38923085 | Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation |
| Q43264540 | Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus |
| Q44571957 | Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients |
| Q45778554 | Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study |
| Q34791985 | Mechanisms of clinically relevant drug interactions associated with tacrolimus |
| Q87469950 | Medication absorption considerations in patients with postpyloric enteral feeding tubes |
| Q42849615 | Mycophenolate acid vs mycophenolate mofetil therapy. |
| Q71778184 | Mycophenolate mofetil |
| Q36544988 | Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability |
| Q35594016 | Mycophenolate mofetil in solid-organ transplantation |
| Q36420503 | Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells |
| Q43604565 | Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions |
| Q46486654 | Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome |
| Q38010596 | Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis. |
| Q34607590 | Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection |
| Q48252498 | Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure. |
| Q34611858 | Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability |
| Q33639354 | New immunosuppressive drugs and lung transplantation: last or least? |
| Q41334079 | New immunosuppressive drugs in organ transplantation |
| Q43280989 | No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation |
| Q46187781 | Non-life-threatening leukopenia in a renal transplant recipient with acute overdose of mycophenolate mofetil |
| Q36727064 | Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? |
| Q34858098 | Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring |
| Q93720325 | PROCEEDINGS OF THE DUTCH SOCIETY OF CLINICAL PHARMACOLOGY AND BIOPHARMACY MEETING OF OCTOBER 4TH 2005 |
| Q53664646 | Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation. |
| Q33764989 | Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. |
| Q37824708 | Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus. |
| Q74245066 | Pharmacokinetic monitoring of mycophenolate mofetil in kidney transplanted patients |
| Q36006086 | Pharmacokinetic principles of immunosuppressive drugs. |
| Q44938164 | Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients |
| Q58896445 | Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid After Enteric-Coated Mycophenolate Versus Mycophenolate Mofetil in Patients With Progressive IgA Nephritis |
| Q50561382 | Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds. |
| Q44101581 | Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy. |
| Q47111663 | Pharmacokinetics of Mycophenolic Acid after Intravenous Administration of Mycophenolate Mofetil to Healthy Cats. |
| Q43628295 | Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation |
| Q46504849 | Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers |
| Q44398329 | Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children |
| Q43554146 | Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus |
| Q77176994 | Pharmacokinetics of mycophenolic acid after renal transplantation |
| Q34425701 | Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients |
| Q46623389 | Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients |
| Q77725077 | Pharmacokinetics of mycophenolic acid in the early period after kidney transplantation |
| Q46111550 | Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment |
| Q36777485 | Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. |
| Q44744553 | Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis |
| Q89774462 | Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients |
| Q85825052 | Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil |
| Q34180482 | Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation |
| Q36629233 | Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors |
| Q46781360 | Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction |
| Q45209671 | Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach |
| Q45972840 | Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. |
| Q46620913 | Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium |
| Q43595945 | Rapid and simultaneous determination of mycophenolic acid and its glucuronide conjugate in human plasma by ion-pair reversed-phase high-performance liquid chromatography using isocratic elution. |
| Q44077266 | Rapid determination of mycophenolic acid in plasma by reversed-phase high-performance liquid chromatography |
| Q34516425 | Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis |
| Q38680524 | Recent Progress in Hepatocyte Culture Models and Their Application to the Assessment of Drug Metabolism, Transport, and Toxicity in Drug Discovery: The Value of Tissue Engineering for the Successful Development of a Microphysiological System |
| Q46137927 | Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance |
| Q46498636 | Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus. |
| Q40837854 | Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. |
| Q88989741 | Role of Purine Biosynthesis in Persistent Methicillin-Resistant Staphylococcus aureus Infection |
| Q37892910 | Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients |
| Q44182189 | Simple determination of mycophenolic acid in human serum by column-switching high-performance liquid chromatography |
| Q55518653 | Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats. |
| Q33852451 | Small molecule drug discovery for Dengue and West Nile viruses: applying experience from hepatitis C virus |
| Q34286869 | Species differences in sinusoidal and canalicular efflux transport of mycophenolic acid 7-O-glucuronide in sandwich-cultured hepatocytes |
| Q74815548 | Stability of mycophenolate mofetil as an extemporaneous suspension |
| Q37690527 | Suppression of autophagy by mycophenolic acid contributes to inhibition of HCV replication in human hepatoma cells |
| Q44799040 | Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection |
| Q40110923 | Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation |
| Q62836306 | The Impact of UGT1A8, UGT1A9, and UGT2B7 Genetic Polymorphisms on the Pharmacokinetic Profile of Mycophenolic Acid After a Single Oral Dose in Healthy Volunteers |
| Q28369328 | The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. |
| Q77956575 | The effect of renal insufficiency on mycophenolic acid protein binding |
| Q37818144 | The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease |
| Q28365923 | The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes |
| Q46513372 | The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice |
| Q45221758 | The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil |
| Q28379426 | The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo |
| Q74662793 | The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function |
| Q47204037 | The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease |
| Q44794659 | The role of generics in transplantation: TM-MMF versus Cellcept in healthy volunteers |
| Q42948459 | The transplanted child: New immunosuppressive agents and the need for pharmacokinetic monitoring |
| Q33957200 | The use of mycophenolate mofetil in transplant recipients |
| Q38206952 | Therapeutic drug monitoring in pediatric renal transplantation |
| Q34660691 | Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary? |
| Q77166104 | Therapeutic monitoring of mycophenolic acid. A consensus panel report |
| Q38860793 | Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy? |
Search more.